Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial
Julius Simoni Leere, Jesper Karmisholt, Maciej Robaczyk, Simon Lykkeboe, Aase Handberg, Emilie Steinkohl, Jens Brøndum Frøkjær, Peter Vestergaard
Topics & Concepts
MedicineCinacalcetDenosumabPrimary hyperparathyroidismPlaceboDouble blindRandomized controlled trialClinical endpointInternal medicineUrologySecondary hyperparathyroidismAlternative medicineParathyroid hormoneOsteoporosisCalciumPathologyParathyroid Disorders and TreatmentsVitamin D Research StudiesDermatological and Skeletal Disorders